Carbamazepine in Severe Liver Disease Due to Alpha-1 Antitrypsin Deficiency (CBZ)

This study is currently recruiting participants. (see Contacts and Locations)
Verified December 2014 by University of Pittsburgh
Sponsor:
Collaborators:
Novartis
Information provided by (Responsible Party):
David Perlmutter, University of Pittsburgh
ClinicalTrials.gov Identifier:
NCT01379469
First received: June 15, 2011
Last updated: December 2, 2014
Last verified: December 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: January 2017
  Estimated Primary Completion Date: January 2017 (Final data collection date for primary outcome measure)
Publications:
Burroughs A.K., and Thalheimer U., Hepatic venous pressure gradient in 2010: optimal measurement is key. Hepatology. 51: 1894-6.
Dodson W., Carbamazepine and oxycarbazepine, Pediatric Epilepsy: Diagnosis and Therapy, P.J. Dodson W.E., Editor. 1993; Demos Publications: New York. 303-314.

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):